This News From Novo: A Warning for Eli Lilly Shareholders
A GLP-1 drug race is moving from injections to pills, reshaping the landscape for Novo Nordisk and Eli Lilly. Here’s ...
This guide weighs the advantages and drawbacks of target date versus lifecycle funds to help you pick the option that best fits your retirement plan.
25,428 articlesA GLP-1 drug race is moving from injections to pills, reshaping the landscape for Novo Nordisk and Eli Lilly. Here’s ...
The Tomi (Tomz) 2026 earnings season offers clues about growth, margins, and strategy. This guide breaks down what to...
Bakkt faces a pivotal year as crypto markets evolve and cash flow models mature. This guide explains what bakkt (bkkt...
Harrow Health's Q1 2026 earnings transcript offers more than numbers—it reveals management's execution plan and what ...
The AI landscape is shifting from a few hardware champions to a broad ecosystem of software, cloud, and microchips. L...
Retirement calculators often misvalue pensions, skewing withdrawal plans. A real-world look at how to adjust strategy...
Stratasys has long been a trailblazer in 3D printing, but the road ahead is proving tougher amid competition and cost...
Canopy Growth sits at the center of sharp investor debate. This article maps three plausible paths for the stock over...
Oil hovers near the $100 mark with talk of a path to $200. Retailers face margin pressure as households trim discreti...
Cerebras exploded higher on its debut, but what comes next for investors? This guide breaks down the hype, the fundam...
Investors are watching CoreWeave's stock slide after a rapid rise. This guide breaks down whether the dip is a buying...
A clear look at Copart's 2026 earnings outlook, the drivers behind revenue, and what this could mean for investors. R...